ARCHIVE OF OLDER REPORTS AND DEVELOPMENTS
(Before January 2001)

JANUARY 2001:


 
 Interferon Appears to Slow Progression, cancer & death in this Japanese Study of Patients with Compensated Cirrhosis
     Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis
     with  PDF  of entire article
(1/31/2001)


   Capravirine (new NNRTI for salvage) Clinical Trials Restricted
Drug Restricted in Patients Until Additional Safety Evaluation Resolved
     What is vasculitis?
(1/29/2001)


   Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
(1/29/2001)


  Biopsy Is Required To Evaluate Liver Disease Severity and Decide When To Begin Therapy
    
The Histologic Spectrum of Chronic Hepatitis C in Patients with Repeatedly Normal ALT (Alanine Aminotransferase): Does Liver Biopsy Make a Difference?

(1/28/2001)


  Pharmacokinetics on Two Pegylated Interferons Reported at AASLD 1999
(1/23/2000)


  NY Gay Black Men Hit Hard by AIDS
(01/25/2001)


  Peg Intron FDA Approved
     First Pegylated Interferon Approved for Marketing in the United States
    
Schering Press Release
(01/24/2001)


  FDA Approves Hepatitis C Therapy: Peg Intron Pricing
     By THE ASSOCIATED PRESS

(01/24/2001)


  Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection: women 39 years or less of age respond better to HCV treatment than men and women older than 40 years
    
Kyushu University Hospital
(01/24/2001)


  Discontinuing Prophylaxis for Opportunistic Infections
     from Jules Levin
(01/18/2001)


  Discontinuing Pneumocystis carinii Prophylaxis
     Editorial from The New England Journal of Medicine -- January 18, 2001 -- Vol. 344, No. 3

(01/18/2001)


  Osteopenia in HIV Infection
     Written for NATAP by Andrew Carr, MD
(01/15/2001)


FDA Hearing, January 11th, 2001, on Salvage Studies:
 
FDA Antiviral Panel on January 11 Endorses 16-Week Viral Endpoints for HIV Salvage Studies and FDA Sends Additional Messages
By Mark Mascolini 
  New Drug Study Design, Toxicities, Resistance Profiles & Interactions
Editorial from Jules Levin, NATAP
  Brief Summary:
16 WEEK STUDY DATA FOR FDA APPROVAL;
DRUG TOXICITIES; NEW STUDY DESIGNS FOR TREATMENT-EXPERIENCED PATIENTS & SALVAGE SITUATIONS

Written by Jules Levin
(01/15/2001)


  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients  
Reported in the current issue of AIDS
    
also in full  PDF  version
(01/15/2001)


  The Role of Liver Biopsy in Chronic Hepatitis C
          in full  PDF  version
BIOPSY STILL REQUIRED
(01/15/2001)


  Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy also in full PDF  version.
(01/10/2001)


  AASLD Report On HCV Therapy Toxicities
     Hemoglobin Decreases from Combination HCV Therapy including Ribavirin  
(01/08/2001)


  When To Begin Therapy:
    
Glasgow & Contrasting Retrovirus Data Presentations
   
Fifth International Congress on Drug Therapy in HIV Infection
- October 22-26, 2000 , Glasgow, Scotland, UK
     Written for NATAP by W. David Hardy, M.D.
     Retrovirus & Glasgow studies: Initial Response To Therapy Based on CD4 & Viral Load Likelihood of Virologic Failure (500 copies/ml)
    
Written by Jules Levin
 (01/05/2001)


  Three Factors Predictive of ALT > 5 times Upper Limit of Normal: HBV, HCV and elevated baseline ALT; 45% with HBV & 33% with HCV had ALT > 5 times Upper limit of Normal
(01/03/2001)


  Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature  
(01/02/2001)


  Osteonecrosis (avascular necrosis) in HIV: A Case-Control Study
      with: Background on Lipids and Corticosteroids and Avascular Necrosis
(01/01/2001)


 Fatigue Affecting People With Liver Disease
(01/01/2001)

OLDER REPORTS AND DEVELOPMENTS FROM: